NEW YORK (GenomeWeb News) – Genomic services company SeqWright will use technologies from Roche subsidiaries 454 Life Sciences and NimbleGen to help drug developer Eli Lilly to identify genetic variants associated with psychiatric diseases, Roche said today.

Under the collaboration, SeqWright will use NimbleGen Sequence Capture technology to enrich around 40 megabases of the human genome, which will then be sequenced using 454 Life Sciences Genome Sequencer FLX System.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

In a statement, National Institutes of Health Director Francis Collins says sexual harassment is "morally indefensible" and "unacceptable."

Octopuses might owe their intelligence to their liberal alterations to their genes, Cosmos reports.

Stat News and ProPublica report that African Americans are underrepresented in cancer clinical trials.

In Cell this week: genomic analysis of abdominal aortic aneurysm, effect of probiotics on the microbiome, and more.

Oct
17
Sponsored by
Lexogen

This webinar will present a method for RNA-seq expression analysis of FFPE-derived RNA samples that are too degraded for successful application of standard RNA-seq techniques.

Oct
25
Sponsored by
Roche

This webinar will detail a comprehensive strategy that a lab has put in place to evaluate  NGS oncology assays for genomic tumor profiling of plasma and tissue samples.